Immuneering (IMRX) Gross Profit (2020 - 2022)
Historic Gross Profit for Immuneering (IMRX) over the last 3 years, with Q4 2022 value amounting to $455.0.
- Immuneering's Gross Profit rose 10273.6% to $455.0 in Q4 2022 from the same period last year, while for Sep 2023 it was $455.0, marking a year-over-year decrease of 9967.9%. This contributed to the annual value of $158830.0 for FY2022, which is 8286.42% down from last year.
- Per Immuneering's latest filing, its Gross Profit stood at $455.0 for Q4 2022, which was up 10273.6% from $19037.0 recorded in Q3 2022.
- Immuneering's Gross Profit's 5-year high stood at $367568.0 during Q3 2020, with a 5-year trough of -$16630.0 in Q4 2021.
- Over the past 3 years, Immuneering's median Gross Profit value was $191847.0 (recorded in 2020), while the average stood at $171718.7.
- Per our database at Business Quant, Immuneering's Gross Profit tumbled by 10866.84% in 2021 and then soared by 10273.6% in 2022.
- Quarter analysis of 3 years shows Immuneering's Gross Profit stood at $191847.0 in 2020, then tumbled by 108.67% to -$16630.0 in 2021, then soared by 102.74% to $455.0 in 2022.
- Its last three reported values are $455.0 in Q4 2022, $19037.0 for Q3 2022, and $46486.0 during Q2 2022.